TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01638819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Cord Blood Stem Cells
Description: One infusion of 60 ml syringe of study product

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02650284

Intervention type: DEVICE
Group type: OTHER
Intervention: Restoris MCK Multicompartmental Knee System
Description: Bicompartmental Knee Replacement
Study: NCT06344286

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Minimal enteral nutrition
Description: The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
Study: NCT01327339

Intervention type: DRUG
Intervention: Ropinirole
Description: Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT01423240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 20 mg
Description: Lurasidone 20 mg once daily orally in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 60 mg
Description: Lurasidone 60 mg once daily orally in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily orally in the evening
Study: NCT04328064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin calcium 40mg
Description: Active drug -Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin calcium 40mg
Description: Active drug -Rosuvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 40 mg placebo for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: 40 mg placebo for 12 months
Study: NCT02551367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: 50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
Study: NCT02285283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01145612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
Study: NCT02344836

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Podcast + mobile diet app
Description: Use of a mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
Study: NCT02551367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hcg hormone
Description: 10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hcg hormone
Description: 10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
Study: NCT02344836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcast + theory-based mobile diet app
Description: Use of a theory-based mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
Study: NCT03704792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan 530 Compact
Description: The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
Study: NCT01521143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cvac
Description: Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cvac
Description: Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.~Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility.
Study: NCT02018809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence Partner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence Partner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence Partner
Study: NCT00906022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astron Pulsar Stent
Description: Stenting with Astron Pulsar

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA alone
Description: Balloon angioplasty alone
Study: NCT04014504

Intervention type: DIAGNOSTIC_TEST
Intervention: Neonatal Hearing Screening Test
Description: neonatal hearing screening test results will be evaluated.
Study: NCT02018809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
Study: NCT03244891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase of central volume
Description: Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:~1. baseline~2. after fluid shift induced by passive head down position at 15 degrees~3. after fluid challenge with Ringer acetate 15ml\*kg in head down position~A total of six steps will be considered for the analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation mode
Description: Each previous step will be done in two respiratory conditions:~1. spontaneous breathing~2. noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome
Study: NCT04012268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: patients will accept medication guided by neurologists
Study: NCT04113031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flywheel squats versus free weight high load squats for explosive actions in football
Description: Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
Study: NCT04921605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFly transcatheter mitral valve clamping system
Description: To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
Study: NCT00333515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Butyrylcholinesterase (HuBChE) derived from human plasma
Description: Administration via IV infusion at a rate of 50 mg/min (2 mL/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Normal saline
Description: Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
Study: NCT02018809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
Study: NCT04113031

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flywheel squats versus free weight high load squats for explosive actions in football
Description: Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flywheel squats versus free weight high load squats for explosive actions in football
Description: Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
Study: NCT02018809

Intervention type: DEVICE
Group type: OTHER
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
Study: NCT00184119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychiatric Intensive Care Unit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Care in whole acute unit
Description: psychiatric acute care as usual
Study: NCT04100161

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Daily dose of 40 g whey protein for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate supplementation
Description: Daily dose of 40 g maltodextrin for 3 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active rehabilitation
Description: Progressive rehabilitation following a muscle strain injury for 3 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active rehabilitation
Description: Progressive rehabilitation following a muscle strain injury for 3 months
Study: NCT02404246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support program
Study: NCT01051011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: as prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: as prescribed
Study: NCT03277248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Placebo
Description: Administered as an IV Infusion.
Study: NCT00857558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: orally administration at 1 mg once a day for 12 weeks
Study: NCT01051011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc weekly, 24 (-52) weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
Study: NCT03780205

Intervention type: OTHER
Intervention: Prescription glasses for bilateral amblyopia
Description: Correction of refractive error with prescription glasses both eyes

Intervention type: OTHER
Intervention: Prescription glasses for unilateral amblyopia
Description: Correction of asymmetric refractive errors with lenses
Study: NCT04563052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Program on Air Pollution as a Health Risk Reduction Strategy
Description: A power point presentation about the health impact of exposure to fine particulate matter (PM2.5) on health. Pm2.5 is found outdoors and indoors. Information will be reviewed about steps to take for the participants to locate the information using a smart phone and steps to take to decrease exposure to prevent illness such as heart disease or strokes.
Study: NCT03766594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
Study: NCT00857558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: orally administration at 2.5 mg once a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: orally administration at 5 mg once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administration once a day for 12 weeks
Study: NCT03766594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
Study: NCT01246453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrapleurally Alteplase vs Intrapleurally Urokinase
Description: Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrapleurally Alteplase vs Intrapleurally Urokinase
Description: Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
Study: NCT01875107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin pre-treatment
Description: insulin pre-treatment of pregnant diabetic patients who receive betamethasone
Study: NCT02684786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reserpine
Description: Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block
Description: Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
Study: NCT02323581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment of Thoracoabdominal Aortic Aneurysm
Description: A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.~This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called fenestrations) that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm.
Study: NCT02669719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chemotherapy followed dendritic cells
Description: Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed and carboplatin
Description: Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
Study: NCT02729792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: intermittent theta burst stimulation (iTBS)
Study: NCT02323581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment of Aortic Arch Aneurysms
Description: An aortic arch aneurysm is an abnormal enlargement (ballooning out) of the main artery (the aorta). The ascending aorta and aortic arch is the first part of the vessel as it exits the heart and makes a turn around the area of the collar bone. This part of the aorta gives branches that supply the head, brain and arms.~The arch branch endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively.
Study: NCT03086941

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
Study: NCT02729792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: intermittent theta burst stimulation (iTBS)
Study: NCT00408161

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard case management treatment
Description: 6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
Study: NCT04789200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX9 Oral Contrast Agent
Description: Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.
Study: NCT01938417

Intervention type: DRUG
Intervention: tobramycin
Study: NCT04094909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rh-endostatin
Description: Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +\[nab\]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period.
Study: NCT00701311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-10004
Description: CC-10004 20 mg per day
Study: NCT05002361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 24 mg intravenous Dexamethasone (6 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: 6 ml of isotonic saline